Drug intelligence / Profile preview

OV835

Development stage: Preclinical
Lead developer: Ovid Therapeutics
Modality: Small Molecules

Overview

OV835 is a novel preclinical drug candidate being developed by Ovid Therapeutics. According to disclosures from the company, OV835 is part of Ovid’s pipeline targeting rare epilepsies and seizure-related disorders. The specific mechanism of action, therapeutic target, or additional preclinical details about OV835 have not been publicly disclosed as of the latest available information.

Beyond the preview

Go deeper on OV835.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on OV835.

Explore the full profile